Loss of MED23 leads to poor prognosis in invasive breast cancer

Aliyeva, T.A.; Joseph, C.; Provenzano, E.; Russell, R.; Caldas, C.; Sonbul, S.; Nolan, C.; Green, A.R.; Rakha, E.A; Ellis, IO.; Mukherjee, A.

Abstract

Purpose of the study: The molecular mechanism of lymphovascular invasion (LVI) which determines the early metastatic phenotype in breast cancer is still not fully understood. Lead from the METABRIC study revealed that MED23 correlated with negative LVI status (p=0.00005). Hence MED23 expression was studied at the protein level for correlations with LVI and other clinical-pathological parameters.
Methods: The METABRIC BC cohort (n=1980) was evaluated for MED23 mRNA expression and prognostic impact externally validated using the online bc-GenExminer 4.0. Correlation between MED23 protein expression with clinicopathological parameters, patient outcome and other biomarkers were explored (Nottingham Tenovus series; n=1255) using immunohistochemistry (IHC).
Results: High MED23 mRNA expression was negatively associated with tumour stage and was differentially expressed in good prognosis integrative clusters 7 and 8 (p

Citation

Aliyeva, T., Joseph, C., Provenzano, E., Russell, R., Caldas, C., Sonbul, S., …Mukherjee, A. (2017). Loss of MED23 leads to poor prognosis in invasive breast cancer.

• Conference Name: Belfast Pathology 2017: 10th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland
• End Date: Jun 23, 2017
• Acceptance Date: Apr 7, 2017
• Publication Date: Jun 20, 2017
• Deposit Date: Jul 7, 2017
• Publicly Available Date: Jul 7, 2017
• Peer Reviewed: Peer Reviewed
• Article Number: O24
• Public URL: https://nottingham-repository.worktribe.com/output/867180
• Publisher URL: https://www.path.org.uk/wp-content/uploads/2017/06/BP2017-PLENARY-ORAL-ABSTRACTS-05.06.17.pdf